FAQ/Help |
Calendar |
Search |
Today's Posts |
11-20-2012, 09:29 AM | #1 | ||
|
|||
Magnate
|
|
||
Reply With Quote |
"Thanks for this!" says: | sim00 (11-20-2012) |
11-21-2012, 01:20 AM | #2 | |||
|
||||
Senior Member
|
This sure sounds like a potential answer to my dilemma. Diagnosed for 18 years, I have bad dyskinesia. And my nervousness (which I never hsad previously) and emotional lability just adds more dyskinesia.
It appears to be not only another delivery method for dopamine, but possibly a better drug to penetrate the blood brain barrier. Quoting from release: ND0612 is based on a proprietary sub-cutaneous levodopa/carbidopa drug formulation that bypasses the digestive tract. It continuously delivers levodopa to achieve straight-line and clinically-significant levodopa blood levels. It also delivers subcutaneous carbidopa to improve the bioavailability of oral levodopa. ND0612 is being developed for administration as an adjunct to oral levodopa via a subcutaneous delivery patch as a new treatment and intervention option in Parkinson's disease treatment. It should reduce off-time and improve the management of motor fluctuations even in patients under the best current standard of care with oral levodopa therapy. Just a word of caution, however. This is only Phase I and look where the sponsoring company is located - (sigh) Peg |
|||
Reply With Quote |
11-21-2012, 08:27 AM | #3 | ||
|
|||
Magnate
|
Quote:
if you look at their website, they don't even mention this patch, they do mention ND0611 which is cabidopa patch. http://www.neuroderm.com/index.html |
||
Reply With Quote |
"Thanks for this!" says: | pegleg (11-21-2012) |
11-22-2012, 01:00 AM | #4 | ||
|
|||
Member
|
I am not going to get "up" about any meds or therapies for our disease. The @#$# FDA is a joke. We have people dying because of KNOWN contamination of a pharmacuetical company as well as a current therapy that is already in use in 40 countries, 40! and they still required complete protocols on it. Which this treatment has been on "fast track" since 2002! I've said it before and I'll say it again. If this were a medication for ED we'd have already seen it.
|
||
Reply With Quote |
11-22-2012, 12:33 PM | #5 | ||
|
|||
Magnate
|
Quote:
taking your frustration out on posters here achieves what? http://www.businessweek.com/articles...dow-pharmacies |
||
Reply With Quote |
11-23-2012, 01:12 PM | #6 | ||
|
|||
Member
|
Quote:
|
||
Reply With Quote |
"Thanks for this!" says: | Arsippe (11-23-2012) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Pa | Parkinson's Disease | |||
NeuroDerm, Ltd. announced today the successful enrollment and dosing in its Phase I c | Parkinson's Disease | |||
Continuous intraduodenal levodopa infusion study | Parkinson's Disease | |||
WE MOVE News...Continuous Levodopa for the Treatment of Parkinson Disease | Parkinson's Disease | |||
Phase II Spheramine trials complete enrollment | Parkinson's Disease |